<DOC>
	<DOCNO>NCT01737346</DOCNO>
	<brief_summary>The combination therapy temozolomide radiation establish standard therapy initial treatment glioblastoma . However , prognosis patient recurrent/ refractory glioblastoma dismal , median survival 3~6 month . There efficient standard care time recurrence progression follow temozolomide administration . Recently , many clinician reassess efficacy second-line chemotherapeutic agent nitrosoureas treatment recurrent/refractory glioblastoma . It important effect agent sustain adverse effect reduce preserve quality life recurrent setting . We realize clinical feature Korean patient different foreign patient . Therefore , mandatory develop new strategy treatment Korean patient . We modify PCV chemotherapy dose administration schedule CCNU procarbazine reduce side effect , especially hematologic problem . The dose CCNU reduce 75mg/m2 interval CCNU procarbazine increase . Moreover , vincristine exclude BBB permeability vincristine poor risk neurotoxicity high . We introduce modified PC chemotherapy regimen treatment recurrent/refractory glioblastoma , first multicenter trial glioblastoma patient Korea .</brief_summary>
	<brief_title>Procarbazine Lomustine Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<criteria>Histologically radiologically confirm progressive recurrent glioblastoma methylated MGMT promoter Within 6 month Stupp regimen ( TMZRT CCRT + adjuvant TMZ ) , After retreatment cyclic TMZ , 6 month later Stupp regimen KPS ≥ 60 % Age ≥ 20 year At least two week apart prior surgery prior chemotherapy Adequate hematologic , liver , renal function Unstained slides central pathology review Signed informed consent Prior malignancy within 5 year except basal cell carcinoma skin , squamous cell carcinoma skin , carcinoma situ cervix maternity breastfeed Evidence active infection within 2 week prior study Previous treatment procarbazine and/or CCNU Evidence leptomeningeal metastasis Unable comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>glioblastoma , recurrent , refractory , CCNU , procarbazine</keyword>
</DOC>